Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

Literature DB >> 8851617

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

Abstract

The new oxazolidinone antimicrobial agents U100592 and U100766 demonstrated good in vitro inhibitory activity against clinical strains of Staphylococcus aureus and Staphylococcus epidermidis regardless of methicillin susceptibility. Both agents appeared bacteriostatic by time-kill analysis. Stable resistance to low multiples of the MIC of either drug could be produced only in methicillin-resistant S. aureus.

Entities: Chemical Species

Mesh：

Substances：

Year: 1996 PMID： 8851617 PMCID： PMC163204

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. Microbial Selection.

Authors: V Bryson; W Szybalski
Journal: Science Date: 1952-07-18 Impact factor: 47.728

2. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound.

Authors: J S Daly; G M Eliopoulos; S Willey; R C Moellering
Journal: Antimicrob Agents Chemother Date: 1988-09 Impact factor: 5.191

3. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.

Authors: D C Eustice; P A Feldman; I Zajac; A M Slee
Journal: Antimicrob Agents Chemother Date: 1988-08 Impact factor: 5.191

4. In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones.

Authors: W Brumfitt; J M Hamilton-Miller
Journal: J Antimicrob Chemother Date: 1988-06 Impact factor: 5.790

5. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.

Authors: A L Barry
Journal: Antimicrob Agents Chemother Date: 1988-01 Impact factor: 5.191

6. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.

Authors: H C Neu; A Novelli; G Saha; N X Chin
Journal: Antimicrob Agents Chemother Date: 1988-04 Impact factor: 5.191

7. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.

Authors: D R Ashtekar; R Costa-Periera; T Shrinivasan; R Iyyer; N Vishvanathan; W Rittel
Journal: Diagn Microbiol Infect Dis Date: 1991 Nov-Dec Impact factor: 2.803

8. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.

Authors: J S Daly; G M Eliopoulos; E Reiszner; R C Moellering
Journal: J Antimicrob Chemother Date: 1988-06 Impact factor: 5.790

9. Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709.

Authors: W Brumfitt; J M Hamilton-Miller
Journal: Diagn Microbiol Infect Dis Date: 1992 Sep-Oct Impact factor: 2.803

10. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.

Authors: A M Slee; M A Wuonola; R J McRipley; I Zajac; M J Zawada; P T Bartholomew; W A Gregory; M Forbes
Journal: Antimicrob Agents Chemother Date: 1987-11 Impact factor: 5.191

10 in total

29 in total

1. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors: Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal: Antimicrob Agents Chemother Date: 2005-01 Impact factor: 5.191

Review 2. Linezolid: a review of its use in the management of serious gram-positive infections.

Authors: C M Perry; B Jarvis
Journal: Drugs Date: 2001 Impact factor: 9.546

Review 3. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics.

Authors: I Chopra; J Hodgson; B Metcalf; G Poste
Journal: Antimicrob Agents Chemother Date: 1997-03 Impact factor: 5.191

Review 4. Linezolid.

Authors: D Clemett; A Markham
Journal: Drugs Date: 2000-04 Impact factor: 9.546

5. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Authors: J Prystowsky; F Siddiqui; J Chosay; D L Shinabarger; J Millichap; L R Peterson; G A Noskin
Journal: Antimicrob Agents Chemother Date: 2001-07 Impact factor: 5.191

6. Clinical experience with linezolid in the treatment of resistant gram-positive infections.

Authors: S J Antony; E Diaz-Vasquez; C Stratton
Journal: J Natl Med Assoc Date: 2001-10 Impact factor: 1.798

7. Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment.

Authors: Jon-David Schwalm; Philippe El-Helou; Christine H Lee
Journal: Can J Infect Dis Date: 2004-03